OncoResponse
Total Raised
$186.1MInvestors Count
20Deal Terms
4Funding, Valuation & Revenue
11 Fundings
OncoResponse has raised $186.1M over 11 rounds.
OncoResponse's latest funding round was a Series D - II for $6M on May 6, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/6/2025 | Series D - II | $6M | 1 | |||
5/18/2023 | Grant | $13M | 5 | |||
5/12/2023 | Series D | $14M | RiverVest Venture Partners, 3B Future Health Fund, ARCH Venture Partners, Bering Capital, Canaan Partners, InterVest, Takeda Ventures, and Undisclosed Investors | 3 | ||
2/15/2022 | Line of Credit | |||||
3/31/2021 | Series C |
Date | 5/6/2025 | 5/18/2023 | 5/12/2023 | 2/15/2022 | 3/31/2021 |
|---|---|---|---|---|---|
Round | Series D - II | Grant | Series D | Line of Credit | Series C |
Amount | $6M | $13M | $14M | ||
Investors | RiverVest Venture Partners, 3B Future Health Fund, ARCH Venture Partners, Bering Capital, Canaan Partners, InterVest, Takeda Ventures, and Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 1 | 5 | 3 |
OncoResponse Deal Terms
4 Deal Terms
OncoResponse's deal structure is available for 4 funding rounds, including their Series B from September 06, 2018.
Round | Series B | Series A - III | Series A - II | Series A |
|---|---|---|---|---|
Funding Date | ||||
Pre-Money Valuation | ||||
Post-Money Valuation | ||||
Amount Raised | ||||
Shares Authorized | ||||
Issuance Price | ||||
Dividend Rate | ||||
Liquidation Preferences | ||||
Liquidation Price | ||||
Participation | ||||
Conversion Price | ||||
Anti Dilution | ||||
General Voting | ||||
Board Voting | ||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A - III | |||||||||||||||
Series A - II | |||||||||||||||
Series A |
OncoResponse Investors
20 Investors
OncoResponse has 20 investors. Canaan Partners invested in OncoResponse's Series D - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/6/2015 | 5/6/2025 | 5 Series A, Series B (2018), Series C (2021), Series D (2023), Series D - II (2025) | Venture Capital | Connecticut | ||
10/6/2015 | 5/6/2025 | 5 Series A, Series B (2018), Series C (2021), Series D (2023), Series D - II (2025) | Venture Capital | Illinois | ||
9/6/2018 | 5/6/2025 | 4 Series B, Series C (2021), Series D (2023), Series D - II (2025) | Venture Capital | Missouri | ||
Government | Texas | |||||
Venture Capital | Monaco |
First funding | 10/6/2015 | 10/6/2015 | 9/6/2018 | ||
|---|---|---|---|---|---|
Last Funding | 5/6/2025 | 5/6/2025 | 5/6/2025 | ||
Investor | |||||
Rounds | 5 Series A, Series B (2018), Series C (2021), Series D (2023), Series D - II (2025) | 5 Series A, Series B (2018), Series C (2021), Series D (2023), Series D - II (2025) | 4 Series B, Series C (2021), Series D (2023), Series D - II (2025) | ||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Government | Venture Capital |
Location | Connecticut | Illinois | Missouri | Texas | Monaco |
OncoResponse Acquisitions
1 Acquisition
OncoResponse acquired 1 company. Their latest acquisition was Paganini Biopharma on November 07, 2017.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
11/7/2017 | Acquired | 1 |
Date | 11/7/2017 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
Compare OncoResponse to Competitors
ImmunoMet Therapeutics develops anti-fibrotic and anti-tumor therapies by targeting cellular metabolism. The company specializes in a lead molecule, IM156, which is a protein complex 1 (PC1) inhibitor designed to affect the oxidative phosphorylation (OXPHOS) pathway in mitochondria, aiming to decrease cell growth in fibrosis and certain cancer cells. It primarily sells to the healthcare and pharmaceutical sectors, with ongoing clinical trials and therapeutic offerings. It was founded in 2015 and is based in Houston, Texas.
Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies targeting myeloid cells within the immunology and oncology sectors. The company offers a portfolio of biotherapeutics, including antagonist antibodies designed to modulate or deplete specific subsets of myeloid cells, to treat blood cancers, solid tumors, and autoimmune diseases. Immune-Onc's pipeline includes several candidates in various stages of clinical development, targeting receptors such as LILRB2 and LILRB4. It was founded in 2016 and is based in Palo Alto, California.
Fortis Therapeutics is a biotechnology company focused on developing therapeutics for cancer treatment. Their offerings include therapies that target CD46 proteins in tumor cells while sparing normal tissues. The company's approach emphasizes precision medicine. It was founded in 2016 and is based in La Jolla, California.
Epsilogen is a biotechnology company that specializes in the development of immunoglobulin E (IgE) antibodies for cancer treatment. The company focuses on creating therapeutic antibodies that target solid tumors, utilizing IgE's properties such as potency, tumor access, and tissue half-life. Epsilogen's lead product, MOv18 IgE, is designed to target ovarian cancer and has progressed to clinical trials. Epsilogen was formerly known as IGEM Therapeutics. It was founded in 2016 and is based in London, United Kingdom.
OncoOne is a biotech company focused on developing precision medicines for the treatment of inflammation and cancer within the healthcare sector. The company develops precision medicines that target tumor-associated molecules and deliver antibody-based therapies to affected organs. OncoOne's main services include the development of therapeutics through its Anti-oxMIF and PreTarg-it platforms, which are aimed at addressing needs in oncology and chronic inflammation. It was founded in 2018 and is based in Klosterneuburg, Austria.
Pathios Therapeutics provides biotechnology solutions. It focuses on oncology and immunology, targeting the G protein-coupled receptor (GPCR) to transform cancer treatment. It develops therapies that inhibit the GPR65 receptor to counteract the immunosuppressive effects of acidic tumor microenvironments in solid tumors. Its approach is designed for the existing cancer immunotherapies by addressing the root cause of immune cell dysfunction within tumors. It was founded in 2017 and is based in Abingdon, United Kingdom.
Loading...